Cic edizioni internazionali
Functional Neurology

Effect of zolpidem in chronic disorders of consciousness: a prospective open-label study

Original Article, 259 - 264
doi: 10.11138/FNeur/2013.28.4.259
Tag this article
Abstract
Enhanced HTML Full text PDF
Zolpidem has been reported as an “awakening drug” in some patients with disorders of consciousness (DOC).
We here present the results of a prospective openlabel study in chronic DOC patients. Sixty patients (35±15 years; 18 females; mean time since insult ± SD: 4±5.5 years; 31 with traumatic etiology) with a diagnosis of vegetative state/unresponsive wakefulness syndrome (n=28) or minimally conscious state (n=32) were behaviorally assessed using the Coma Recovery Scale-Revised (CRS-R) before and one hour after administration of 10 mg of zolpidem. At the group level, the diagnosis did not change after intake of zolpidem (p=0.10) and CRS-R total scores decreased (p=0.01). Twelve patients (20%) showed improved behaviors and/or CRS-R total scores after zolpidem administration but in only one patient was the diagnosis after zolpidem intake found to show a significant improvement (functional object use), which suggested a change of diagnosis. However, in this patient, a double-blind placebo-controlled trial was performed in order to better specify the effects of zolpidem, but the patient, on this trial, failed to show any clinical improvements.
The present open-label study therefore failed to show any clinically significant improvement (i.e., change of Effect of zolpidem in chronic disorders of consciousness: a prospective open-label study diagnosis) in any of the 60 studied chronic DOC patients

Vol. XXXI (No. 4) 2016 October/December

  1. The challenge of in vivo tissue characterization, connectivity and big data
    Gandini Wheeler-Kingshott C.
    doi: 10.11138/FNeur/2016.31.4.189
  2. Network functional connectivity and whole-brain functional connectomics to investigate cognitive decline in neurodegenerative conditions
    Dipasquale O., Cercignani M.
    doi: 10.11138/FNeur/2016.31.4.191
  3. Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias
    Del Sole A., Malaspina S., Magenta Biasina A.
    doi: 10.11138/FNeur/2016.31.4.205
  4. Modeling white matter microstructure
    Duval T., Stikov N., Cohen-Adad J.
    doi: 10.11138/FNeur/2016.31.4.217
  5. Reconstructing contralateral fiber tracts: methodological aspects of cerebello-thalamocortical pathway reconstruction
    Palesi F., Tournier J-D, Calamante F., Muhlert N., Castellazzi G., Chard D., D'Angelo E., Wheeler-Kingshott C.G.
    doi: 10.11138/FNeur/2016.31.4.229
  6. Impact of cerebellar atrophy on cortical gray matter and cerebellar peduncles as assessed by voxel-based morphometry and high angular resolution diffusion imaging
    Dayan M., Olivito G., Molinari M., Cercignani M., Bozzali M., Leggio M.
    doi: 10.11138/FNeur/2016.31.4.239
  7. Connectivity measures in the Poffenberger paradigm indicate hemispheric asymmetries
    Erbil N., Yagcioglu S.
    doi: 10.11138/FNeur/2016.31.4.249
  8. Main effects and interactions of cerebral hemispheres, gender, and age in the calculation of volumes and asymmetries of selected structures of episodic memory
    Ramirez-Carmona R., Garcia-Lazaro H.G., Dominguez-Corrales B., Aguilar-Castañeda E., Roldan-Valadez E.
    doi: 10.11138/FNeur/2016.31.4.257
Last Viewed articles: la lista degli ultimi x visitati.
  1. Effect of zolpidem in chronic disorders of consciousness: a prospective open-label study
    Thonnard M., Gosseries O., Demertzi A., Lugo Z., Vanhaudenhuyse A., Bruno M.A., Chatelle C., Thibaut A., Charland-Verville V., Habbal D., Schnakers C., Laureys S.
    doi: 10.11138/FNeur/2013.28.4.259
credits